Determining the Safety and Effectiveness of ENDOR Oral Combination Drug in the Treatment of Patients With COVID-19: A Randomized Controlled Trial

Minoo  Mohraz; Seyed Ehsan  Kazerooni; Arash  Seifi; Seyed Ali Dehghan  Manshadi; Seyed Ahmad Seyed  Alinaghi; Fereshteh Shahmari  Golestan; Samaneh  Nikkhoo; Alireza  Abdollahi; Sirous  Jafari; Mahdokht  Hajrahimi

doi:10.18502/acta.v63i5.20348

Minoo Mohraz Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Seyed Ehsan Kazerooni Department of Infectious Diseases, Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Arash Seifi Department of Infectious Diseases, Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Seyed Ali Dehghan Manshadi Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Seyed Ahmad Seyed Alinaghi Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Fereshteh Shahmari Golestan Department of Nursing, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Samaneh Nikkhoo Department of Nursing, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Alireza Abdollahi Department of Pathology, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Sirous Jafari Department of Infectious Diseases, Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Mahdokht Hajrahimi Department of Pulmonary and Critical Care Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/acta.v63i5.20348

Keywords: Anti-inflammatory drugs; COVID-19; Endor; Hospitalized

Abstract

The novel coronavirus caused by SARS-CoV-2 is still a public health concern as it can have dire consequences. Anti-inflammatory drugs are promising. Therefore, this study aimed to determine the safety and effectiveness of the ENDOR oral combination drug in the treatment of patients with COVID-19. This double-blinded, randomized controlled trial was conducted at the Imam Khomeini Hospital complex in Tehran, Iran. All COVID-19 patients who were admitted to the Imam Khomeini hospital complex from April 2022 to April 2023 and who were 18-75-Year-Old signed the consent form to participate in this study, were not pregnant, and did not need mechanical ventilation at admission. In this study of 200 patients (50% in the Endor group and 50% in the placebo group), 56.8% were male, and the mean age was 65.02±14.94. There were no statistically significant differences observed between the Endor and control groups across time for temperature (P=.075), WBC (P=.095), CRP (P=.108), sodium (P=.323), or calcium (P=.352). The slope of the decrease in ESR and the body temperature, as well as the slope of the increase in oxygen saturation in the Endor group, was higher than in the control group. Statistically significant differences between the Endor and control groups over time for respiratory rate (P=.003), oxygen saturation (P<.001), and potassium (P=.031) were observed. The decreasing slope of the respiratory rate in the Endor group was significantly higher than in the control group. ENDOR with anti-inflammatory features helps COVID-19 hospitalized patients recover faster by improving oxygen saturation, lowering fever, and decreasing respiratory rate.